Antisense Therapeutics Limited

Symbol: ANP.AX

ASX

0.058

AUD

Market price today

  • -3.4108

    P/E Ratio

  • -0.0892

    PEG Ratio

  • 52.29M

    MRK Cap

  • 0.00%

    DIV Yield

Antisense Therapeutics Limited (ANP-AX) Financial Statements

On the chart you can see the default numbers in dynamics for Antisense Therapeutics Limited (ANP.AX). Companys revenue shows the average of 0.752 M which is 0.133 % gowth. The average gross profit for the whole period is 0.728 M which is 0.133 %. The average gross profit ratio is 0.401 %. The net income growth for the company last year performance is 0.951 % which equals -0.836 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Antisense Therapeutics Limited, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 2.205. In the realm of current assets, ANP.AX clocks in at 12.692 in the reporting currency. A significant portion of these assets, precisely 10.967, is held in cash and short-term investments. This segment shows a change of -0.430% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0.048 in the reporting currency. This figure signifies a year_over_year change of -0.259%. Shareholder value, as depicted by the total shareholder equity, is valued at 9.976 in the reporting currency. The year over year change in this aspect is -0.528%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 1.659, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000

balance-sheet.row.cash-and-short-term-investments

55.181119.26
4.1
2.9
4.3
1.9
4.8
6.8
1.3
4
5
2.3
1.7
3.1
6.4
7.6
8.2
8.8
14.4
6.5
9.4
13.7

balance-sheet.row.short-term-investments

0000
0
0
2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

1.921.71.80.6
0.7
0.6
0.3
0.4
0.4
0.7
1.2
1
0.6
0
0
1.8
3.3
0.4
0.1
0.1
0.2
0.1
0.1
0

balance-sheet.row.inventory

0000
0.2
-0.6
0
0.2
0
0
0
0
0
0
0
0
0
0
0
0.4
0.3
0
0
0

balance-sheet.row.other-current-assets

5.571.50.50.7
0.3
0.8
0.2
0
0.1
0.1
0.1
0.2
0.1
0.1
0.1
0.1
0.2
0.1
0.3
0
0
0.9
0.1
0

balance-sheet.row.total-current-assets

61.2712.722.26.7
5.2
3.7
4.8
2.5
5.3
7.7
2.6
5.2
5.7
2.4
1.8
5
9.9
8
8.6
9.3
14.9
7.5
9.6
13.7

balance-sheet.row.property-plant-equipment-net

0.690.20.20.3
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0.1
0

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
1.9
3.2
4.4
5.7
6.4

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
1.9
3.2
4.4
5.7
6.4

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

-0.69-0.2-0.2-0.3
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-non-current-assets

0.690.20.20.3
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0.5
1.9
3.2
4.5
5.8
6.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

61.9512.822.47
5.4
3.7
4.8
2.5
5.3
7.7
2.7
5.2
5.7
2.4
1.8
5
9.9
8
9.1
11.2
18.2
12
15.3
20.1

balance-sheet.row.account-payables

4.7910.30.2
0.1
0.2
0.1
0.2
0.2
0.2
0.1
0.2
0
0.1
0
0.6
1
1.9
0
0.2
0.1
0.3
1.8
0

balance-sheet.row.short-term-debt

0.090.10.10.1
0.1
0
0
0
0
0
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0.0500.10.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

4.821.80.80.9
0.7
0.7
0.5
0.5
0.5
0.4
0.3
0.4
0.4
0.4
0.4
0.4
2.4
0.1
0.3
0.1
0.9
0
0
0.1

balance-sheet.row.total-non-current-liabilities

0.060.10.10.2
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0.1
0
0
0
0
0
0

balance-sheet.row.other-liabilities

0.23000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0.140.10.20.3
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

9.912.91.31.3
0.8
0.9
0.6
0.7
0.8
0.6
0.6
0.6
0.4
0.4
0.5
1.1
3.5
2
0.3
0.4
1
0.4
1.9
0.1

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

393.0598.398.177
69.1
63.9
62.4
57.7
56.7
56.7
52.4
51.8
49.7
44.7
42.2
41.4
41.4
39.3
37.2
33.8
33.8
23.7
19.5
20.4

balance-sheet.row.retained-earnings

-356.94-92.3-80.9-75.1
-67
-61.1
-58.2
-55.9
-53.1
-50.6
-51.3
-48.3
-45.8
-44
-42.2
-38.8
-36.1
-34
-29.2
-23.7
-17.4
-12.8
-6.7
-0.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

443.93.8
2.4
-0.2
-0.2
0
1
1
1
1.1
1.4
1.4
1.4
1.3
1
0.8
0.7
0.7
0.7
0.7
0.7
0

balance-sheet.row.other-total-stockholders-equity

11.94000
0
0.2
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.7
0

balance-sheet.row.total-stockholders-equity

52.051021.15.7
4.5
2.8
4.2
1.9
4.6
7.1
2.1
4.6
5.3
2
1.3
3.9
6.3
6
8.8
10.9
17.1
11.6
13.5
20

balance-sheet.row.total-liabilities-and-stockholders-equity

61.9512.822.47
5.4
3.7
4.8
2.5
5.3
7.7
2.7
5.2
5.7
2.4
1.8
5
9.9
8
9.1
11.2
18.2
12
15.3
20.1

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

52.051021.15.7
4.5
2.8
4.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

61.95---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0000
0
0
2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

0.140.10.20.3
0.1
0
0
0
0
0
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

-55.04-10.8-19-5.7
-3.9
-2.9
-1.9
-1.9
-4.8
-6.8
-1.3
-4
-5
-2.3
-1.7
-3.1
-6.4
-7.6
-8.2
-8.8
-14.4
-6.5
-9.4
-13.7

Cash Flow Statement

The financial landscape of Antisense Therapeutics Limited has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -687.559. The company recently extended its share capital by issuing 0, marking a difference of 0.130 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -29291.000 in the reporting currency. This is a shift of 6.486 from the previous year. In the same period, the company recorded 0.1, 0, and -0.09, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000

cash-flows.row.net-income

-11.38-11.4-5.8-8.1
-5.9
-2.9
-2.3
-2.8
-2.5
0.7
-3
-2.5
-1.8
-1.8
-3.4
-2.6
-2.1
-4.8
-5.5
-6.3
-4.6
-6.1
-6.3
-0.4

cash-flows.row.depreciation-and-amortization

0.10.10.10.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0.5
1.5
1.3
1.3
1.3
0.7
0

cash-flows.row.deferred-income-tax

-0.38-0.61.1-1.5
-2.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0.210.20.11.4
2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0.340.3-1.20.1
-0.3
-0.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-receivables

0.340.3-1.20.1
-0.3
-0.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-non-cash-items

2.953.1-2.12.1
1.9
0.3
2.3
-0.2
0.5
0.6
-0.1
-0.4
-0.6
-0.1
2.1
-0.6
-1.3
1.7
0
-0.6
1.1
4.8
1.6
0.4

cash-flows.row.net-cash-provided-by-operating-activities

-8.15000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.03000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0000
0
2.4
-2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

0000
0
2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

0000
0
-2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-0.03000
0
2.4
-2.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.debt-repayment

0-0.1-0.1-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0

cash-flows.row.common-stock-issued

0022.68.5
5.5
1.6
5
0.1
0
4.4
0.6
1.8
5.5
2.5
0
0
2.3
2.1
3.6
0
10.4
4.5
12.9
0

cash-flows.row.common-stock-repurchased

00-1.5-0.6
-0.3
-0.1
-0.3
0
0
-0.2
-0.1
0
-0.5
0
0
0
-0.1
0
0
0
-0.3
-0.3
-0.7
0

cash-flows.row.dividends-paid

00-0.1-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1.5
0

cash-flows.row.other-financing-activites

-0.0900.10.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.2
0
0
0
2.3
0

cash-flows.row.net-cash-used-provided-by-financing-activities

-0.09-0.1217.8
5.1
1.5
4.7
0
0
4.2
0.5
1.8
5
2.5
0
0
2.2
2
3.4
0
10.1
4.2
12.8
0

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-8.27-8.313.22
1.2
1
0
-2.9
-2
5.5
-2.7
-1
2.6
0.6
-1.3
-3.3
-1.2
-0.6
-0.6
-5.6
7.9
-2.8
8.7
0

cash-flows.row.cash-at-end-of-period

-8.271119.26
4.1
2.9
1.9
1.9
4.8
6.8
1.3
4
5
2.3
1.7
3.1
6.4
7.6
8.2
8.8
14.4
6.5
9.4
0

cash-flows.row.cash-at-beginning-of-period

019.264.1
2.9
1.9
1.9
4.8
6.8
1.3
4
5
2.3
1.7
3.1
6.4
7.6
8.2
8.8
14.4
6.5
9.4
0.6
0

cash-flows.row.operating-cash-flow

-8.15-8.2-7.8-5.8
-3.9
-2.9
0
-2.9
-2
1.3
-3.1
-2.8
-2.4
-1.9
-1.3
-3.3
-3.4
-2.7
-4
-5.6
-2.2
0
-4.1
0

cash-flows.row.capital-expenditure

-0.03000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0

cash-flows.row.free-cash-flow

-8.18-8.2-7.8-5.8
-4
-2.9
0
-2.9
-2
1.3
-3.1
-2.8
-2.4
-1.9
-1.3
-3.3
-3.4
-2.7
-4
-5.6
-2.2
0
-4.1
0

Income Statement Row

Antisense Therapeutics Limited's revenue saw a change of 0.000% compared with the previous period. The gross profit of ANP.AX is reported to be 1.55. The company's operating expenses are 13.34, showing a change of 75.333% from the last year. The expenses for depreciation and amortization are 0.1, which is a 0.067% change from the last accounting period. Operating expenses are reported to be 13.34, which shows a 75.333% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.753% year-over-year growth. The operating income is -13.34, which shows a 0.753% change when compared to the previous year. The change in the net income is 0.951%. The net income for the last year was -11.38.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000

income-statement-row.row.total-revenue

1.581.61.80.6
0.7
0.6
0
0.1
1
3.9
0
0
0
0
0
0
6.4
0.8
0
0
0
0
0
0

income-statement-row.row.cost-of-revenue

0.0300.10.1
0.2
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

1.551.51.70.5
0.5
0.4
0
0.1
1
3.9
0
0
0
0
0
0
6.4
0.8
0
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

10.16---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

1.51---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

1.32---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

01.60.20.2
0.3
0.1
0.3
0.4
0.4
0.7
1.2
1.1
1
0.5
0.3
0.4
0.2
0.3
0.1
0.3
0.7
0
0.8
-0.1

income-statement-row.row.operating-expenses

13.313.37.68.7
6.7
3.6
2.6
3.3
4.1
3.9
4.3
3.8
2.9
2.4
3.9
4.6
7.5
5.6
5.9
7.1
6.3
6.6
6.7
0.3

income-statement-row.row.cost-and-expenses

13.3413.37.68.7
6.7
3.6
2.6
3.3
4.1
3.9
4.3
3.8
2.9
2.4
3.9
4.6
7.5
5.6
5.9
7.1
6.3
6.6
6.7
0.3

income-statement-row.row.interest-income

0.390.400
0
0.1
0
0.1
0.1
0.1
0.1
0.2
0.1
0.1
0.1
0.3
0.4
0.5
0.4
0.6
0.7
0.4
0.3
0

income-statement-row.row.interest-expense

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

1.32---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.391.61.80.6
0.8
0.6
0.3
0.4
0.4
0.7
1.2
1.1
1
0.5
0.3
0.4
0.2
0.3
0.1
0.3
0.7
0
0.4
-0.1

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

01.60.20.2
0.3
0.1
0.3
0.4
0.4
0.7
1.2
1.1
1
0.5
0.3
0.4
0.2
0.3
0.1
0.3
0.7
0
0.8
-0.1

income-statement-row.row.total-operating-expenses

0.391.61.80.6
0.8
0.6
0.3
0.4
0.4
0.7
1.2
1.1
1
0.5
0.3
0.4
0.2
0.3
0.1
0.3
0.7
0
0.4
-0.1

income-statement-row.row.interest-expense

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.010.10.10.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0.5
1.5
1.3
1.3
1.3
0.7
0

income-statement-row.row.ebitda-caps

-11.75---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-11.77-13.3-7.6-8.7
-6.7
-3.6
-2.6
-3.2
-3.1
0
-4.3
-3.8
-2.9
-2.4
-3.9
-4.6
-1.1
-5.6
-5.9
-7.1
-6.3
-6.6
-6.7
-0.3

income-statement-row.row.income-before-tax

-11.38-11.4-5.8-8.1
-5.9
-2.9
-2.3
-2.8
-2.5
0.7
-3
-2.5
-1.8
-1.8
-3.4
-3.9
-0.5
-4.8
-5.5
-6.3
-5
-6.1
-6.3
-0.4

income-statement-row.row.income-tax-expense

0-0.400
0
-0.6
0.3
-0.1
-0.1
-0.1
-0.1
-0.2
-0.1
-0.1
0
-1.3
1.6
0.3
-0.4
-6.3
-5
-6.1
-6.3
-0.4

income-statement-row.row.net-income

-11.38-11.4-5.8-8.1
-5.9
-2.3
-2.3
-2.8
-2.5
0.7
-3
-2.5
-1.8
-1.8
-3.4
-2.6
-2.1
-4.8
-5.5
-6.3
-4.6
-6.1
-6.3
-0.4

Frequently Asked Question

What is Antisense Therapeutics Limited (ANP.AX) total assets?

Antisense Therapeutics Limited (ANP.AX) total assets is 12843028.000.

What is enterprise annual revenue?

The annual revenue is 1086468.000.

What is firm profit margin?

Firm profit margin is 0.979.

What is company free cash flow?

The free cash flow is -0.012.

What is enterprise net profit margin?

The net profit margin is -7.203.

What is firm total revenue?

The total revenue is -7.447.

What is Antisense Therapeutics Limited (ANP.AX) net profit (net income)?

The net profit (net income) is -11379828.000.

What is firm total debt?

The total debt is 142099.000.

What is operating expences number?

The operating expences are 13344975.000.

What is company cash figure?

Enretprise cash is 10967259.000.